Cotización Innate Pharma - IPHA

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

2.9901

Postura de Compra

2.99

Postura de Venta

3.00

Volume Operado de la Acción

13,470,381

1.47 Rango del Día 3.5107

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

240.563M

Precio Anterior

1.55

Precio de Apertura

1.50

Hora

200

2.9901

(formt)

Última hora de negociación

15:31:44

Volumen financiero

US$ 31,759,727

Precio Promedio Ponderado

2.3577

Volumen promedio (3 m)

Acciones en circulación

80,453,282

Rendimiento del Dividendo

Ratio Precio/Utilidad

-20.19

Beneficio por acción (BPA)

-0.09

turnover

61.64M

Beneficio neto

-7.57M

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therap... Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others. Mostrar más

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.innate-pharma.com

Sede

Marseille, Bouches-du-rhone, Fra

Fundado

Innate Pharma SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IPHA. The last closing price for Innate Pharma was US$1.55. Over the last year, Innate Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Innate Pharma currently has 80,453,282 shares in issue. The market capitalisation of Innate Pharma is US$124.70 million. Innate Pharma has a price to earnings ratio (PE ratio) of -20.19.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanés

Les résultats mettent en évidence des signes précoces prometteurs selon lesquels lacutamab pourrait aider à soulager certains des symptômes les plus éprouvants des lymphomes T cutanés...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
PTPIPetros Pharmaceuticals Inc	US$ 0.4428 (34.26%)	5.48M
SSKNStrata Skin Sciences Inc	US$ 3.49 (16.53%)	468
NXTTNext Technology Holding Inc	US$ 2.19 (11.73%)	450
COEPCoeptis Therapeutics Holdings Inc	US$ 0.195 (10.67%)	34.08k
JZXNJiuzi Holdings Inc	US$ 1.98 (10.61%)	844
BNOXBionomics Ltd	US$ 0.28 (-13.34%)	301.54k
BONBon Natural Life Ltd	US$ 1.51 (-11.18%)	1.13k
SMCLGraniteShares 2X Long SMCI Daily ETF	US$ 20.759 (-7.61%)	209
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 53.86 (-6.97%)	174.87k
DBVTDBV Technologies SA	US$ 3.3378 (-6.77%)	1.12k
PTPIPetros Pharmaceuticals Inc	US$ 0.4428 (34.26%)	5.48M
SMCISuper Micro Computer Inc	US$ 35.1295 (-3.66%)	4.34M
GOEVCanoo Inc	US$ 0.1325 (1.88%)	2.1M
VCITVanguard Intermediate Term Corporate Bond	US$ 81.33 (0.01%)	2.07M
NVDANVIDIA Corporation	US$ 134.15 (-0.08%)	1.68M